EyePoint Settles DOJ Kickback Probe for $4.7M, Enters 5-Year Oversight
EYPT sits 41% above its 52-week low of $9.4.
Summary
EyePoint settled DOJ allegations of kickbacks to ambulatory surgery centers for DEXYCU sales, agreeing to pay $4.68 million plus interest and $166,500 in attorneys' fees. The company also entered a five-year Corporate Integrity Agreement with the OIG-HHS, effective July 13, 2026, which imposes ongoing compliance obligations and monitoring. This resolves a legal overhang but adds regulatory scrutiny and costs at a time when the company is burning cash on its DURAVYU pipeline and revenue has collapsed. The settlement amount is modest relative to market cap, but the CIA signals heightened government oversight that could distract management and constrain commercial practices. The 8-K filed today confirms the terms; no prior news had reported this resolution.
At the time of this announcement, EYPT was trading at $13.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $9.40 to $19.11. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.